Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Purchased by Deltec Asset Management LLC

Deltec Asset Management LLC lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,716,373 shares of the biopharmaceutical company's stock after purchasing an additional 100,000 shares during the period. Ocular Therapeutix accounts for about 4.2% of Deltec Asset Management LLC's investment portfolio, making the stock its 4th biggest holding. Deltec Asset Management LLC owned about 1.71% of Ocular Therapeutix worth $19,911,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of OCUL. GF Fund Management CO. LTD. bought a new stake in shares of Ocular Therapeutix during the 4th quarter valued at $28,000. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $43,000. AlphaQuest LLC bought a new stake in shares of Ocular Therapeutix in the 4th quarter worth approximately $53,000. GAMMA Investing LLC grew its stake in shares of Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 8,112 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 8,446 shares in the last quarter. Institutional investors own 59.21% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. William Blair began coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating for the company. Royal Bank Of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday, May 29th. Needham & Company LLC dropped their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities set a $19.00 target price on Ocular Therapeutix in a research report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $17.33.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL traded down $0.20 during mid-day trading on Friday, hitting $8.13. The stock had a trading volume of 1,711,252 shares, compared to its average volume of 1,404,692. The company has a 50 day moving average of $7.87 and a two-hundred day moving average of $7.82. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. The firm has a market cap of $1.30 billion, a PE ratio of -7.07 and a beta of 1.42. Ocular Therapeutix, Inc. has a twelve month low of $5.79 and a twelve month high of $11.78.

Insider Activity

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the transaction, the insider now directly owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,079 shares of company stock worth $208,739 over the last 90 days. 2.30% of the stock is currently owned by company insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.